Regionally Specific Cortical Thinning in Children with Sickle Cell Disease

Regionally Specific Cortical Thinning in Children with Sickle Cell Disease
复制标题

DOI:
10.1093/cercor/bhn193
复制
发表时间:
2009-07-01
期刊:
影响因子:
3.7
通讯作者:
Jones, Richard A.
Jones, Richard A.
中科院分区:
医学2区
文献类型:
--
作者:
Kirk, Gregory R.;Haynes, M. Ryan;Jones, Richard A.

文献摘要

被引文献

相似文献

镰状细胞病(SCD)是一种慢性疾病,在生命的第一个十年中神经系统并发症的发生率很高。在这项回顾性研究中,对常规磁共振成像/磁共振血管造影未检测到异常的SCD儿童进行了皮质厚度检查。使用年龄匹配的健康对照作为比较,探索SCD的皮质厚度的区域差异。由于皮质成熟的年龄依赖性变化,基于年龄(5-11岁; 12-21岁)对SCD(n = 28)和对照组(n = 29)进行比较分析。在两个年龄组的SCD患者中发现了明显的变薄区域。在老年SCD组中,这些变薄区域的数量、空间范围和显著性(P < 0.001)增加。感兴趣区(ROI)定义在老年组中高度显著变薄的区域,然后映射到年轻组; ROI数据的多参数线性回归分析表明SCD受试者的皮质变薄显著(P < 0.001),楔前叶和后扣带回的变薄区域最大。区域特异性差异表明,皮质厚度可作为SCD中无症状损伤的标志物,因此可能是识别神经系统后遗症风险的SCD患者的有用工具。
Sickle cell disease (SCD) is a chronic disease with a significant rate of neurological complications in the first decade of life. In this retrospective study, cortical thickness was examined in children with SCD who had no detectable abnormalities on conventional magnetic resonance imaging/magnetic resonance angiography. Regional differences in cortical thickness from SCD were explored using age-matched healthy controls as comparison. A comparison analysis was done for SCD (n = 28) and controls (n = 29) based on age (5-11; 12-21 years), due to the age-dependent variation in cortex maturation. Distinct regions of thinning were found in SCD patients in both age groups. The number, spatial extent, and significance (P < 0.001) of these areas of thinning were increased in the older SCD group. Regions of interest (ROIs) were defined on the areas of highly significant thinning in the older group and then mapped onto the younger cohort; a multiparametric linear regression analysis of the ROI data demonstrated significant (P < 0.001) cortical thinning in SCD subjects, with the largest regions of thinning in the precuneus and the posterior cingulate. The regionally specific differences suggest that cortical thickness may serve as a marker for silent insults in SCD and hence may be a useful tool for identifying SCD patients at risk for neurological sequelae.